Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Neurosci ; 25(2): 168-179, 2022 02.
Article in English | MEDLINE | ID: mdl-34931070

ABSTRACT

Bacterial products can act on neurons to alter signaling and function. In the present study, we found that dorsal root ganglion (DRG) sensory neurons are enriched for ANTXR2, the high-affinity receptor for anthrax toxins. Anthrax toxins are composed of protective antigen (PA), which binds to ANTXR2, and the protein cargoes edema factor (EF) and lethal factor (LF). Intrathecal administration of edema toxin (ET (PA + EF)) targeted DRG neurons and induced analgesia in mice. ET inhibited mechanical and thermal sensation, and pain caused by formalin, carrageenan or nerve injury. Analgesia depended on ANTXR2 expressed by Nav1.8+ or Advillin+ neurons. ET modulated protein kinase A signaling in mouse sensory and human induced pluripotent stem cell-derived sensory neurons, and attenuated spinal cord neurotransmission. We further engineered anthrax toxins to introduce exogenous protein cargoes, including botulinum toxin, into DRG neurons to silence pain. Our study highlights interactions between a bacterial toxin and nociceptors, which may lead to the development of new pain therapeutics.


Subject(s)
Anthrax , Bacillus anthracis , Bacterial Toxins , Induced Pluripotent Stem Cells , Animals , Anthrax/microbiology , Anthrax/therapy , Bacillus anthracis/metabolism , Bacterial Toxins/metabolism , Ganglia, Spinal/metabolism , Humans , Induced Pluripotent Stem Cells/metabolism , Mice , Nociceptors/metabolism , Pain , Receptors, Peptide/metabolism
2.
Sci Adv ; 5(1): eaau7196, 2019 01.
Article in English | MEDLINE | ID: mdl-30746458

ABSTRACT

Although botulinum neurotoxin serotype A (BoNT/A) products are common treatments for various disorders, there is only one commercial BoNT/B product, whose low potency, likely stemming from low affinity toward its human receptor synaptotagmin 2 (hSyt2), has limited its therapeutic usefulness. We express and characterize two full-length recombinant BoNT/B1 proteins containing designed mutations E1191M/S1199Y (rBoNT/B1MY) and E1191Q/S1199W (rBoNT/B1QW) that enhance binding to hSyt2. In preclinical models including human-induced pluripotent stem cell neurons and a humanized transgenic mouse, this increased hSyt2 affinity results in high potency, comparable to that of BoNT/A. Last, we solve the cocrystal structure of rBoNT/B1MY in complex with peptides of hSyt2 and its homolog hSyt1. We demonstrate that neuronal surface receptor binding limits the clinical efficacy of unmodified BoNT/B and that modified BoNT/B proteins have promising clinical potential.


Subject(s)
Botulinum Toxins, Type A/metabolism , Botulinum Toxins, Type A/pharmacology , Recombinant Proteins/metabolism , Synaptotagmin II/metabolism , Animals , Botulinum Toxins, Type A/chemistry , Botulinum Toxins, Type A/genetics , Crystallography, X-Ray , Female , Glycine/metabolism , Humans , Induced Pluripotent Stem Cells/drug effects , Male , Mice, Inbred C57BL , Mice, Transgenic , Muscle, Skeletal/drug effects , Muscle, Smooth/drug effects , Mutation , Neurons/drug effects , Neurons/metabolism , Protein Engineering , Rabbits , Rats, Sprague-Dawley , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology , Static Electricity , Synaptotagmin II/chemistry , Synaptotagmin II/genetics
3.
PLoS One ; 12(10): e0185628, 2017.
Article in English | MEDLINE | ID: mdl-28982136

ABSTRACT

Botulinum neurotoxins (BoNTs) are used extensively as therapeutic agents. Serotypes A and B are available as marketed products. Higher doses of BoNT/B are required to reach an efficacy similar to that of products containing BoNT/A. Advances in our understanding of BoNT/B mechanism of action have afforded the opportunity to make rational modifications to the toxin aimed at increasing its activity. Recently, a mutation in the light chain of BoNT/B (S201P) was described that increases the catalytic activity of the isolated BoNT/B light chain in biochemical assays. In this study, we have produced two full-length recombinant BoNT/B toxins in E.coli-one wild type (rBoNT/B1) and one incorporating the S201P mutation (rBoNT/B1(S201P)). We have compared the activity of these two molecules along with a native BoNT/B1 in biochemical cell-free assays and in several biological systems. In the cell-free assay, which measured light-chain activity alone, rBoNT/B1(S201P) cleaved VAMP-2 and VAMP-1 substrate with an activity 3-4-fold higher than rBoNT/B1. However, despite the enhanced catalytic activity of rBoNT/B1(S201P), there was no significant difference in potency between the two molecules in any of the in vitro cell-based assays, using either rodent spinal cord neurons or cortical neurons. Similarly in ex vivo tissue preparations rBoNT/B1(S201P) was not significantly more potent than rBoNT/B1 at inhibiting either diaphragm or detrusor (bladder) muscle activity in C57BL/6N and CD1 mice. Finally, no differences between rBoNT/B1 and rBoNT/B1(S201P) were observed in an in vivo digit abduction score (DAS) assay in C57BL/6N mice, either in efficacy or safety parameters. The lack of translation from the enhanced BoNT/B1(S201P) catalytic activity to potency in complex biological systems suggests that the catalytic step is not the rate-limiting factor for BoNT/B to reach maximum efficacy. In order to augment the efficacy of BoNT/B in humans, strategies other than enhancing light chain activity may need to be considered.


Subject(s)
Botulinum Toxins, Type A/pharmacology , Vesicle-Associated Membrane Protein 1/metabolism , Vesicle-Associated Membrane Protein 2/metabolism , Animals , Botulinum Toxins, Type A/genetics , Catalysis , Cells, Cultured , Cloning, Molecular , Escherichia coli/genetics , In Vitro Techniques , Mice , Mice, Inbred C57BL , Patch-Clamp Techniques , Rats
4.
Nat Commun ; 8(1): 53, 2017 07 03.
Article in English | MEDLINE | ID: mdl-28674381

ABSTRACT

Botulinum neurotoxin B is a Food and Drug Administration-approved therapeutic toxin. However, it has lower binding affinity toward the human version of its major receptor, synaptotagmin II (h-Syt II), compared to mouse Syt II, because of a residue difference. Increasing the binding affinity to h-Syt II may improve botulinum neurotoxin B's therapeutic efficacy and reduce adverse effects. Here we utilized the bacterial adenylate cyclase two-hybrid method and carried out a saturation mutagenesis screen in the Syt II-binding pocket of botulinum neurotoxin B. The screen identifies E1191 as a key residue: replacing it with M/C/V/Q enhances botulinum neurotoxin B binding to human synaptotagmin II. Adding S1199Y/W or W1178Q as a secondary mutation further increases binding affinity. Mutant botulinum neurotoxin B containing E1191M/S1199Y exhibits ~11-fold higher efficacy in blocking neurotransmission than wild-type botulinum neurotoxin B in neurons expressing human synaptotagmin II, demonstrating that enhancing receptor binding increases the overall efficacy at functional levels. The engineered botulinum neurotoxin B provides a platform to develop therapeutic toxins with improved efficacy.Humans are less sensitive to the therapeutic effects of botulinum neurotoxin B (BoNT/B) than the animal models it is tested on due to differences between the human and the mouse receptors. Here, the authors engineer BoNT/B to improve its affinity to human receptors and enhance its therapeutic efficacy.


Subject(s)
Botulinum Toxins, Type A/genetics , Synaptotagmin II/metabolism , Acetylcholine Release Inhibitors/pharmacology , Animals , Botulinum Toxins, Type A/metabolism , Botulinum Toxins, Type A/pharmacology , Humans , Mutagenesis, Site-Directed , Neurons/drug effects , Neurons/metabolism , Patch-Clamp Techniques , Protein Binding/genetics , Rats , Recombinant Proteins , Two-Hybrid System Techniques
5.
J Med Chem ; 55(3): 1021-46, 2012 Feb 09.
Article in English | MEDLINE | ID: mdl-22224594

ABSTRACT

Tissue transglutaminase 2 (TG2) is a multifunctional protein primarily known for its calcium-dependent enzymatic protein cross-linking activity via isopeptide bond formation between glutamine and lysine residues. TG2 overexpression and activity have been found to be associated with Huntington's disease (HD); specifically, TG2 is up-regulated in the brains of HD patients and in animal models of the disease. Interestingly, genetic deletion of TG2 in two different HD mouse models, R6/1 and R6/2, results in improved phenotypes including a reduction in neuronal death and prolonged survival. Starting with phenylacrylamide screening hit 7d, we describe the SAR of this series leading to potent and selective TG2 inhibitors. The suitability of the compounds as in vitro tools to elucidate the biology of TG2 was demonstrated through mode of inhibition studies, characterization of druglike properties, and inhibition profiles in a cell lysate assay.


Subject(s)
Acrylamides/chemical synthesis , GTP-Binding Proteins/antagonists & inhibitors , Huntington Disease/drug therapy , Sulfonamides/chemical synthesis , Transglutaminases/antagonists & inhibitors , Acrylamides/chemistry , Acrylamides/pharmacology , Animals , Caco-2 Cells , Cell Membrane Permeability , HEK293 Cells , Humans , In Vitro Techniques , Male , Mice , Microsomes, Liver/metabolism , Models, Molecular , Piperazines/chemical synthesis , Piperazines/chemistry , Piperazines/pharmacology , Protein Glutamine gamma Glutamyltransferase 2 , Pyridines/chemical synthesis , Pyridines/chemistry , Pyridines/pharmacology , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Pyrimidines/pharmacology , Rats , Structure-Activity Relationship , Sulfonamides/chemistry , Sulfonamides/pharmacology
6.
Protein Sci ; 19(1): 168-73, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19937655

ABSTRACT

The Mapkap kinases 2 and 3 (MK2 and MK3) have been implicated in intracellular signaling pathways leading to the production of the pro-inflammatory cytokine tumor necrosis factor alpha. MK2 has been pursued by the biopharmaceutical industry for many years for the development of a small molecule anti-inflammatory treatment and drug-like inhibitors have been described. The development of some of these compounds, however, has been slowed by the absence of a high-resolution crystal structure of MK2. Herein we present a high-resolution (1.9 A) crystal structure of the highly homologous MK3 in complex with a pharmaceutical lead compound. While all of the canonical features of Ser/Thr kinases in general and MK2 in particular are recapitulated in MK3, the detailed analysis of the binding interaction of the drug-like ligand within the adenine binding pocket allows relevant conclusions to be drawn for the further design of potent and selective drug candidates.


Subject(s)
Crystallography/methods , Intracellular Signaling Peptides and Proteins/chemistry , Intracellular Signaling Peptides and Proteins/metabolism , Protein Serine-Threonine Kinases/chemistry , Protein Serine-Threonine Kinases/metabolism , Catalytic Domain , Humans , Intracellular Signaling Peptides and Proteins/genetics , Ligands , Models, Molecular , Protein Binding , Protein Serine-Threonine Kinases/genetics , Recombinant Fusion Proteins
7.
Antimicrob Agents Chemother ; 46(6): 1793-9, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12019092

ABSTRACT

Lipid A is the hydrophobic anchor of lipopolysaccharide (LPS) and forms the major lipid component of the outer monolayer of the outer membrane of gram-negative bacteria. Lipid A is required for bacterial growth and virulence, and inhibition of its biosynthesis is lethal to bacteria. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) is a metalloenzyme that catalyzes the second step in the biosynthesis of lipid A. Inhibitors of LpxC have previously been shown to have antibiotic activities. We have screened a metalloenzyme inhibitor library for antibacterial activities against an Escherichia coli strain with reduced LpxC activity. From this screen, a series of sulfonamide derivatives of the alpha-(R)-amino hydroxamic acids, exemplified by BB-78484 and BB-78485, have been identified as having potent inhibitory activities against LpxC in an in vitro assay. Leads from this series showed gram-negative selective activities against members of the Enterobacteriaceae, Serratia marcescens, Morganella morganii, Haemophilus influenzae, Moraxella catarrhalis, and Burkholderia cepacia. BB-78484 was bactericidal against E. coli, achieving 3-log killing in 4 h at a concentration 4 times above the MIC, as would be predicted for an inhibitor of lipid A biosynthesis. E. coli mutants with decreased susceptibility to BB-78484 were selected. Analysis of these mutants revealed that resistance arose as a consequence of mutations in the fabZ or lpxC genes. These data confirm the antibacterial target of BB-78484 and BB-78485 and validate LpxC as a target for gram-negative selective antibacterials.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Enzyme Inhibitors/pharmacology , Naphthalenes/pharmacology , Sulfonamides/pharmacology , Amidohydrolases/genetics , Bacteria/enzymology , Bacteria/genetics , DNA, Recombinant/genetics , Drug Resistance, Microbial , Drug Synergism , Escherichia coli/genetics , Genotype , Hydro-Lyases/genetics , Microbial Sensitivity Tests , Mutation/genetics , Plasmids/genetics , Reverse Transcriptase Polymerase Chain Reaction , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...